Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8746900 | 1.00 | PLA2G2C (0.53) | PLA2G2CLPAR1LPAR3USP2CYP3A4 | |
| SCHEMBL30385293 | 0.89 | PRKCA (0.57) | LPAR1LPAR3ALDH1A1LPAR2PRKCA | |
| SCHEMBL15158724 | 0.89 | LPAR1 (0.60) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL26045825 | 0.89 | LPAR1 (0.60) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL4904539 | 0.87 | LPAR1 (0.58) | PLA2G2CLPAR1LPAR3ALDH1A1LPAR2 | |
| SCHEMBL2197348 | 0.87 | LPAR1 (0.58) | PLA2G2CLPAR1LPAR3ALDH1A1LPAR2 | |
| SCHEMBL5015534 | 0.85 | USP2 (0.52) | PLA2G2CUSP2CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL2709921 | 0.85 | PRKCA (0.61) | ALDH1A1PRKCA | |
| SCHEMBL14526262 | 0.85 | USP2 (0.51) | PLA2G2CLPAR1LPAR3USP2CYP3A4 | |
| SCHEMBL17577412 | 0.83 | LPAR1 (0.50) | PLA2G2CLPAR1LPAR3USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206206-B2 | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD. (IL) | 2015-12-08 | — | — | US | disclosed |
| EP-2826370-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2826369-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2348866-B1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD (IL) | 2015-01-07 | — | — | EP | disclosed |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | VASCULAR BIOGENICS LTD. (IL) | 2013-08-08 | — | — | US | disclosed |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | LPO, GPX4, ALOX15B | PLA2G2C 1093/4885LPAR1 305/4885LPAR3 417/4885 |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | LPO, GPX4, ALOX15B | PLA2G2C 1093/4885LPAR1 305/4885LPAR3 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.